<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04196036</url>
  </required_header>
  <id_info>
    <org_study_id>S60974</org_study_id>
    <nct_id>NCT04196036</nct_id>
  </id_info>
  <brief_title>Day 3 Fresh Transfer Followed by Day 3 or Day 5 Vitrification of Supernumerary Embryos</brief_title>
  <official_title>Cumulative Pregnancy Rates and Direct Healthcare Cost Analysis of Two Different Strategies: Fresh Cleavage-stage Embryo Transfer (ET) on Day 3 With Vitrification of Supernumerary Embryos on Day 3 Versus Day 5</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sophie Debrock</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>KU Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This monocenter academic study aims to evaluate the effectiveness and cost effectiveness of
      two different strategies: fresh Embryo Transfer (ET) on day 3 followed by cryopreservation of
      cleavage-stage (Day 3) embryos versus blastocyst-stage (Day 5) embryos.

      The primary outcome is the cumulative pregnancy rate after all transfers (fresh and/or frozen
      embryo transfer cycles which might take about 1 year), up to two sequential cycles. The
      secondary outcome concerns a cost analysis of both strategies from the healthcare payer's
      perspective.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cumulative pregnancy rate</measure>
    <time_frame>Cumulative pregnancy is measured after two consecutive IVF cycles including fresh and frozen transfers which might take about 1 year</time_frame>
    <description>The cumulative pregnancy rate after all transfers (fresh and/or frozen embryo transfer cycles)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cost analysis</measure>
    <time_frame>Cumulative pregnancy is measured after two consecutive IVF cycles including fresh and frozen transfers which might take about 1 year</time_frame>
    <description>cost analysis of day 3 and day 5 vitrification strategy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Subfertility</condition>
  <arm_group>
    <arm_group_label>Day 3 vitrification</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Day of vitrification of supernumerary embryos is day 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Day 5 vitrification</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Day of vitrification of supernumerary embryos is day5</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Day of vitrification</intervention_name>
    <description>Supernumerary embryos after fresh transfer on Day 3 after oocyte aspiration are either vitrified on Day 3 or are kept in culture until Day 5 and vitrified on Day 5</description>
    <arm_group_label>Day 3 vitrification</arm_group_label>
    <arm_group_label>Day 5 vitrification</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  subfertile women planned for the first or second oocyte retrieval for in vitro
             fertilisation (IVF)/Intracytoplasmic sperm injection (ICSI) treatment

          -  who are older than 18 and less than 38 years old

          -  who have normal Follicle Stimulating Hormone (FSH) and normal Anti-Mullerian Hormone
             (AMH) levels

        Exclusion Criteria:

          -  treatment with donor oocytes or donor embryos

          -  patients planned for Pre-implantation Genetic Diagnosis (PGD)

          -  Patients with BMI&gt;30

          -  patients with endometriosis grade III-IV
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>37 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sophie Debrock, PhD</last_name>
    <phone>+3216341208</phone>
    <email>sophie.debrock@uzleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>annemie mengels</last_name>
    <phone>+32161308</phone>
    <email>annemie.mengels@uzleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Leuven University Fertility Center</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie G Debrock, PhD</last_name>
      <phone>00 32 16 34 08 12</phone>
      <email>Sophie.debrock@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>sophie G Debrock, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 15, 2018</study_first_submitted>
  <study_first_submitted_qc>December 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2019</study_first_posted>
  <last_update_submitted>January 29, 2020</last_update_submitted>
  <last_update_submitted_qc>January 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>KU Leuven</investigator_affiliation>
    <investigator_full_name>Sophie Debrock</investigator_full_name>
    <investigator_title>Professor, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

